Monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are effective, well-tolerated, and safe for the preventive treatment of patients with both episodic migraine (EM) and chronic migraine (CM) (1–3). This evidence concerns the gene CALCA and erythema multiforme.